TOP TEN perturbations for 11760025_x_at (Homo sapiens)

Organism: Homo sapiens
Gene: 11760025_x_at
Selected probe(set): 220838_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 11760025_x_at (220838_at) across 5880 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):1.8815899
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.5509892
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):1.5104351
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

engineered skin substitute study 2 (early) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):-1.2898912
Number of Samples:6 / 2
Experimental engineered skin substitute study 2 (early)
Human skin substitutes tissue samples collected after 3 and 7 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):1.2304306
Number of Samples:2 / 3
Experimental glioma study 16 (LN-215)
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

engineered skin substitute study 1 (late) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):-1.1849356
Number of Samples:3 / 2
Experimental engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.

normal skeletal muscle tissue (pre-training; active) / normal skeletal muscle tissue (pre-training; sedentary)

Relative Expression (log2-ratio):-1.1834116
Number of Samples:17 / 24
Experimental normal skeletal muscle tissue (pre-training; active)
Vastus lateralis muscle tissue biopsy samples from 17 young healthy active Caucasian men. Resting skeletal muscle biopsies were taken before the endurance training program. Average parameters of patients were: age=29±6 y, height=1.82±0.5 m, body mass=81.8±9 kg, VO2max=4.1±0.5 L.min-1.
Control normal skeletal muscle tissue (pre-training; sedentary)
Vastus lateralis muscle tissue biopsy samples from 24 young sedentary healthy Caucasian men. Resting skeletal muscle biopsies were taken before the endurance training program. Average parameters of patients were: age=23±1 y, height=1.82±0.02 m, body mass=78.6±2.7 kg, VO2max=3.71±0.55 L.min-1.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):1.1763439
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-1.1404781
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

engineered skin substitute study 1 (intermediate) / engineered skin substitute study 1 (early)

Relative Expression (log2-ratio):-1.0844774
Number of Samples:3 / 2
Experimental engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.
Control engineered skin substitute study 1 (early)
Human skin substitutes tissue samples collected after 3 days in culture.